- Live news: Eli Lilly buys Point Biopharma at 90% premium Financial Times
- Eli Lilly to Buy Point Biopharma. Cancer Treatment Stock Surges 84%. Barron’s
- Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies | Eli Lilly and Company Investors | Eli Lilly and Company
- Will Weakness in POINT Biopharma Global Inc.’s (NASDAQ:PNT) Stock Prove Temporary Given Strong Fundamentals? Yahoo Finance
- Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies PR Newswire
- View Full coverage on Google News
Recent Posts
- CCC councillors chase stakeholders before boycotting same meeting
- Govt Plans To Take Over Third-party Motor Vehicle Insurance – pindula.co.zw
- ‘Daisy Jones & the Six,’ ‘Beverly Hills Cop: Axel Foley’ Among Winners of California on Location Awards – Variety
- The new method of ZnIn2S4 synthesis on the titania nanotubes substrate with enhanced stability and photoelectrochemical performance | Scientific Reports – Nature.com
- NASA’s Webb space telescope reveals rocky planets can form in extreme environments – CGTN
Recent Comments
No comments to show.